Jason Zemansky
Stock Analyst at B of A Securities
(4.89)
# 53
Out of 5,152 analysts
52
Total ratings
80.56%
Success rate
47.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EIKN Eikon Therapeutics | Initiates: Buy | $34 | $15.16 | +124.27% | 1 | Mar 2, 2026 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $6 | $1.95 | +207.69% | 1 | Jan 21, 2026 | |
| KROS Keros Therapeutics | Maintains: Neutral | $18 → $19 | $13.77 | +37.98% | 3 | Nov 28, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $17 → $26 | $22.68 | +14.64% | 6 | Nov 28, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $10 → $8 | $4.82 | +65.98% | 5 | Nov 18, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $8 → $7 | $0.61 | +1,042.86% | 6 | Nov 18, 2025 | |
| INSM Insmed | Maintains: Buy | $142 → $187 | $149.88 | +24.77% | 11 | Oct 27, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $52 → $56 | $62.27 | -10.07% | 5 | Oct 2, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $28.18 | +10.01% | 4 | Apr 1, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $36 → $29 | $8.55 | +239.18% | 2 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $31 | $21.62 | +43.39% | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $2.9 → $2.5 | $2.91 | -14.09% | 5 | Jun 20, 2024 |
Eikon Therapeutics
Mar 2, 2026
Initiates: Buy
Price Target: $34
Current: $15.16
Upside: +124.27%
Inhibikase Therapeutics
Jan 21, 2026
Initiates: Buy
Price Target: $6
Current: $1.95
Upside: +207.69%
Keros Therapeutics
Nov 28, 2025
Maintains: Neutral
Price Target: $18 → $19
Current: $13.77
Upside: +37.98%
Arcus Biosciences
Nov 28, 2025
Maintains: Neutral
Price Target: $17 → $26
Current: $22.68
Upside: +14.64%
Rocket Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $4.82
Upside: +65.98%
Werewolf Therapeutics
Nov 18, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $0.61
Upside: +1,042.86%
Insmed
Oct 27, 2025
Maintains: Buy
Price Target: $142 → $187
Current: $149.88
Upside: +24.77%
Cytokinetics
Oct 2, 2025
Maintains: Neutral
Price Target: $52 → $56
Current: $62.27
Upside: -10.07%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $28.18
Upside: +10.01%
Kura Oncology
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $8.55
Upside: +239.18%
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $21.62
Upside: +43.39%
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $2.91
Upside: -14.09%